$BCYC Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.15 up 82.35% YoY
• Reported revenue of $34.06M up 190.37% YoY
• Bicycle Therapeutics reported cash and cash equivalents of $469.9M as of September 30, 2026, with expected cash runway into 2030, as stated in quarterly results.